Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Next Previous
Trial Profile

A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aficamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms SEQUOIA-HCM
  • Sponsors Cytokinetics

Most Recent Events

  • 19 Oct 2026 According to a Cytokinetics media release, company announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients.
  • 02 Oct 2026 According to Cytokinetics media release, data from the trial will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.
  • 30 Jul 2026 According to Cytokinetic Media release, Medicines and Healthcare products Regulatory Agency has granted MYQORZO a marketing authorization across the United Kingdom for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy in eligible adult patients. At the same time the National Institute for Health and Care Excellence has issued guidance recommending aficamten for use in eligible adult patients in England and Wales.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top